MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of “Hold” by Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have received an average recommendation of “Hold” from the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.7692.

Several equities research analysts have issued reports on the stock. Wedbush lowered their price target on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $10.00 target price (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a research report on Monday, September 29th. HC Wainwright reissued a “buy” rating and set a $32.00 price target (up from $26.00) on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Needham & Company LLC decreased their price target on MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 30th. Finally, Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th.

MoonLake Immunotherapeutics Trading Up 2.3%

NASDAQ MLTX opened at $16.71 on Thursday. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The stock’s 50 day moving average price is $14.15 and its two-hundred day moving average price is $29.78. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -5.03 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter in the prior year, the business posted ($0.56) EPS. As a group, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the transaction, the chief executive officer owned 2,948,577 shares in the company, valued at approximately $44,464,541.16. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kristian Reich sold 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the transaction, the insider directly owned 72,908 shares in the company, valued at approximately $1,099,452.64. This trade represents a 64.07% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 402,908 shares of company stock valued at $5,987,162. Insiders own 12.02% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth approximately $28,000. Bank of America Corp DE boosted its position in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the period. Covestor Ltd acquired a new position in shares of MoonLake Immunotherapeutics in the third quarter valued at $46,000. Finally, BNP Paribas Financial Markets raised its position in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after purchasing an additional 1,158 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.